MedPath

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Phase 2
Completed
Conditions
Hidradenitis Suppurativa
Interventions
Drug: Placebo matching Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 2
Registration Number
NCT05819398
Lead Sponsor
Boehringer Ingelheim
Brief Summary

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS. People who have previously taken specific medicines such as immunosuppressive biologics other than Tumor necrosis factor (TNF) inhibitors cannot take part.

This study has 2 parts. In Part 1, participants are divided into 4 groups of almost equal size. 3 groups get different doses of spesolimab, 1 group gets placebo. All participants get injections into a vein or under the skin. Placebo injections look like spesolimab injections, but do not contain any medicine. Every participant has an equal chance of being in each group. In the beginning, participants get the study medicine every week and later every 2 weeks. After 4 months, participants in the placebo group switch to spesolimab treatment.

In Part 2, participants are divided into 2 groups. One group gets a suitable dose of spesolimab that was found in Part 1 of the study. The other group gets placebo. After 4 months, participants in the placebo group switch to spesolimab treatment.

Participants join only one of the two parts. They are in the study for about 1 year. During this time, they visit the study site in the beginning every week and later every 2 weeks. Some of the visits can be done at the participant's home instead of the study site. The doctors regularly check participants' HS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.

Detailed Description

Main endpoints for Part 2 will be supported by Part 1 results available at time of primary analysis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
209
Inclusion Criteria
  1. Of full age of consent at screening.
  2. Signed and dated written informed consent in accordance with International Council on Harmonisation-Good clinical practice (ICH-GCP) and local legislation prior to admission to the trial.
  3. Moderate to severe HS.
  4. HS lesions in at least 2 distinct anatomic areas.
  5. Biologic naive or Tumor Necrosis Factor inhibitor (TNFi)-exposed for HS.
  6. For biologic naïve, inadequate response to an adequate course of appropriate oral antibiotics for treatment of HS in the last 1 year prior to the Baseline visit, as per investigator discretion. All participants must have previous exposure to antibiotics for HS.
  7. Total AN count of greater than or equal to 5.
  8. Total dT count of at least 1 at Baseline visit. Further inclusion criteria apply.
Exclusion Criteria
  1. Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  2. Prior exposure to any immunosuppressive/immunomodulatory biologic other than TNFi for HS.
  3. Prior exposure to Interleukin 36 receptor (IL-36R) inhibitors including spesolimab.
  4. Treated with any investigational device or investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives of the drug, whichever is longer.
  5. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
  6. Participants with history of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients.
  7. Participants with a transplanted organ (with exception of a corneal transplant >12 weeks prior to screening) or who has ever received stem cell therapy (e.g., Remestemcel-L).
  8. Participants with any documented active or suspected malignancy or history of malignancy within 5 years prior to the screening visit, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix.

Further exclusion criteria apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Part I: Low dose groupSpesolimab Formulation 1-
Part I: Low dose groupSpesolimab Formulation 2-
Part I: Medium dose groupSpesolimab Formulation 1-
Part I: Medium dose groupSpesolimab Formulation 2-
Part I: High dose groupSpesolimab Formulation 1-
Part I: High dose groupSpesolimab Formulation 2-
Part I: Placebo groupPlacebo matching Spesolimab Formulation 1-
Part I: Placebo groupPlacebo matching Spesolimab Formulation 2-
Part II: Active (treatment) groupSpesolimab Formulation 2-
Part II: Placebo groupPlacebo matching Spesolimab Formulation 2-
Primary Outcome Measures
NameTimeMethod
Part 1: Percent change from baseline in Draining fistula/tunnel (dT) count at Week 8At baseline and at week 8
Secondary Outcome Measures
NameTimeMethod
Part 1: Percent change from baseline in dT count at Week 16 (part 1)At baseline and at week 16
Part 1: Absolute change from baseline in International hidradenitis suppurativa severity score system (IHS4) value at Week 8At baseline and at week 8

The IHS4 score is arrived at by the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4).

A total score of 3 or less signifies mild, 4-10 signifies moderate and 11 or higher signifies severe disease.

Part 1: Absolute change from baseline in IHS4 value at Week 16At baseline and at week 16
Part 1: Occurrence of treatment emergent adverse events (TEAEs)up to 64 weeks

Trial Locations

Locations (158)

Dokkyo Medical University Hospital

🇯🇵

Tochigi, Shimotsuga-gun, Japan

First OC Dermatology

🇺🇸

Fountain Valley, California, United States

Dermatology Research Associates

🇺🇸

Los Angeles, California, United States

Integrative Skin Science and Research-Sacramento-69402

🇺🇸

Sacramento, California, United States

Clinical Trials Research Institute

🇺🇸

Thousand Oaks, California, United States

Ziaderm Research

🇺🇸

North Miami Beach, Florida, United States

ForCare Clinical Research, Inc.

🇺🇸

Tampa, Florida, United States

Olympian Clinical Research-Tampa-69560

🇺🇸

Tampa, Florida, United States

Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995

🇺🇸

Indianapolis, Indiana, United States

University of Michigan Health System

🇺🇸

Ann Arbor, Michigan, United States

Oakland Hills Dermatology, PC

🇺🇸

Auburn Hills, Michigan, United States

Skin Specialists, P.C.

🇺🇸

Omaha, Nebraska, United States

AXIS Clinicals

🇺🇸

Fargo, North Dakota, United States

Unity Clinical Research

🇺🇸

Oklahoma City, Oklahoma, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Palmetto Clinical Trial Services

🇺🇸

Greenville, South Carolina, United States

Center for Clinical Studies-Houston-58806

🇺🇸

Houston, Texas, United States

Progressive Clinical Research

🇺🇸

San Antonio, Texas, United States

STAT Research

🇦🇷

Caba, Argentina

Hospital Italiano de Buenos Aires

🇦🇷

Caba, Argentina

Hospital Alemán

🇦🇷

Capital Federal, Argentina

Centro de Investigaciones Medicas Mar del Plata

🇦🇷

Mar del Plata, Argentina

University Hospital Bulovka

🇨🇿

Prague, Czechia

Instituto de Especialidades de la Salud Rosario

🇦🇷

Rosario, Argentina

Sanatorio 9 de Julio S.A.

🇦🇷

San Miguel de Tucumán, Argentina

Holdsworth House Medical Practice

🇦🇺

Sydney, New South Wales, Australia

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

Alfred Hospital

🇦🇺

Melbourne, Victoria, Australia

Brussels - UNIV Saint-Luc

🇧🇪

Bruxelles, Belgium

Centre Hospitalier Universitaire de Liège

🇧🇪

Liège, Belgium

Medical Center "Kordis"

🇧🇬

Pleven, Bulgaria

ASMC-IPSMC-skin and Veneral Diseases

🇧🇬

Sofia, Bulgaria

Diagnostic Consultative Center Alexandrovska

🇧🇬

Sofia, Bulgaria

DCC "Fokus-5-LZIP" OOD

🇧🇬

Sofia, Bulgaria

Medical Military Academy MHAT Sofia

🇧🇬

Sofia, Bulgaria

MHAT Prof Stoyan Kirkovich AD

🇧🇬

Stara Zagora, Bulgaria

SimcoDerm Medical and Surgical Dermatology Centre

🇨🇦

Barrie, Ontario, Canada

Guelph Dermatology Research

🇨🇦

Guelph, Ontario, Canada

Dr. S. K. Siddha Medicine Professional Corporation

🇨🇦

Newmarket, Ontario, Canada

York Dermatology Clinic and Research Centre

🇨🇦

Richmond Hill, Ontario, Canada

Centro Internacional de Estudios Clínicos (CIEC)

🇨🇱

Comuna De Recoleta, Chile

Clínica Dermacross S.A.

🇨🇱

Vitacura, Chile

Peking University First Hospital

🇨🇳

Beijing, China

Univ. Hospital Kralovske Vinohrady

🇨🇿

Praha, Czechia

The First Hospital of Jilin University

🇨🇳

Changchun, China

The Second Xiangya Hospital Of Central South University

🇨🇳

Changsha, China

West China Hospital

🇨🇳

Chengdu, China

Southern Medical University Dermatology Hospital

🇨🇳

Guangzhou, China

The First Affiliated Hospital, Zhejiang University

🇨🇳

Hangzhou, China

Shanghai Skin Disease Hospital

🇨🇳

Shanghai, China

HOP Pontchaillou

🇫🇷

Rennes, France

Xinjiang Uygur Autonomous Region People's Hospital

🇨🇳

Urumqi, China

Wuhan Union Hospital

🇨🇳

Wuhan, China

University Hospital Ostrava

🇨🇿

Ostrava, Czechia

Aarhus University Hospital

🇩🇰

Aarhus, Denmark

Bispebjerg og Frederiksberg Hospital

🇩🇰

København NV, Denmark

Sjællands Universitetshospital

🇩🇰

Roskilde, Denmark

HOP la Milétrie

🇫🇷

Poitiers, France

Suomen Terveystalo oy Tampere

🇫🇮

Tampere, Finland

HOP Privé Antony

🇫🇷

Antony, France

HOP Edouard Herriot

🇫🇷

Lyon, France

HOP Timone

🇫🇷

Marseille, France

HOP l'Archet

🇫🇷

Nice, France

HOP Saint-Louis

🇫🇷

Paris, France

Fachklinik Bad Bentheim

🇩🇪

Bad Bentheim, Germany

Charite Universitätsmedizin Berlin KöR

🇩🇪

Berlin, Germany

Katholisches Klinikum Bochum gGmbH

🇩🇪

Bochum, Germany

Universitätsmedizin Göttingen, Georg-August-Universität

🇩🇪

Göttingen, Germany

Hautmedizin Saar

🇩🇪

Merzig, Germany

Klinikum Oldenburg AöR

🇩🇪

Oldenburg, Germany

University General Hospital Attikon

🇬🇷

Athens, Greece

Attikon University Hospital

🇬🇷

Athens, Greece

Andreas Syggros Hospital of Cutaneous & Venereal Diseases

🇬🇷

Athens, Greece

General Hospital of Thessaloniki "Ippokrateio"

🇬🇷

Thessaloniki, Greece

General Hospital "G. Papageorgiou"

🇬🇷

Thessaloniki, Greece

Haemek Medical Center

🇮🇱

Afula, Israel

Rambam Health Care Campus

🇮🇱

Haifa, Israel

Rabin Medical Center Beilinson

🇮🇱

Petach Tikva, Israel

Sheba MC

🇮🇱

Ramat Gan, Israel

Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

AOU Università degli Studi della Campania Luigi Vanvitelli

🇮🇹

Napoli, Italy

Azienda Ospedaliera Universitaria Pisana

🇮🇹

Pisa, Italy

Pol. Universitario Tor Vergata

🇮🇹

Roma, Italy

Istituto Dermopatico Dell'Immacolata - IDI - IRCCS

🇮🇹

Roma, Italy

Japan Community Healthcare Organization Chukyo Hospital

🇯🇵

Aichi, Nagoya, Japan

Nagoya City University Hospital

🇯🇵

Aichi, Nagoya, Japan

Fujita Health University Hospital

🇯🇵

Aichi, Toyoake, Japan

Fukuoka University Hospital

🇯🇵

Fukuoka, Fukuoka, Japan

Kurume University Hospital

🇯🇵

Fukuoka, Kurume, Japan

Ogaki Municipal Hospital

🇯🇵

Gifu, Ogaki, Japan

Meiwa Hospital

🇯🇵

Hyogo, Nishinomiya, Japan

University of Tsukuba Hospital

🇯🇵

Ibaraki, Tsukuba, Japan

Tohoku University Hospital

🇯🇵

Miyagi, Sendai, Japan

Okayama University Hospital

🇯🇵

Okayama, Okayama, Japan

National Hospital Organization Okayama Medical Center

🇯🇵

Okayama, Okayama, Japan

University of the Ryukyus Hospital

🇯🇵

Okinawa, Nakagami-gun, Japan

Kansai Medical University Hospital

🇯🇵

Osaka, Hirakata, Japan

Shiga University of Medical Science Hospital

🇯🇵

Shiga, Otsu, Japan

The University of Tokyo Hospital

🇯🇵

Tokyo, Bunkyo-ku, Japan

Nihon University Itabashi Hospital

🇯🇵

Tokyo, Itabashi-ku, Japan

Tokyo Medical University Hospital

🇯🇵

Tokyo, Shinjuku-ku, Japan

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Hallym University Kangnam Sacred Heart Hospital

🇰🇷

Seoul, Korea, Republic of

Hospital of Lithuanian University of Health Sciences Kauno Klinikos

🇱🇹

Kaunas, Lithuania

Vilnius University Hospital, Santariskiu

🇱🇹

Vilnius, Lithuania

Hospital Pulau Pinang-Pulau Pinang-21953

🇲🇾

Georgetown Pulau Pinang, Malaysia

Hospital Sultanah Aminah

🇲🇾

Johor Bahru, Malaysia

Hospital Sultan Ismail

🇲🇾

Johor Bahru, Malaysia

Hospital Raja Perempuan Zainab II, Kota Bharu

🇲🇾

Kota Bahru, Malaysia

Hospital Kuala Lumpur

🇲🇾

Kuala Lumpur, Malaysia

Hospital Sultanah Nur Zahirah

🇲🇾

Kuala Trengganu, Malaysia

Sarawak General Hospital

🇲🇾

Kuching, Malaysia

Sunway Medical Centre

🇲🇾

Selangor Darul Ehsan, Malaysia

Derma Norte del Bajio S.C.

🇲🇽

Aguascalientes, Mexico

Grupo Clinico CATEI S.C.

🇲🇽

Guadalajara, Mexico

Hospital Universitario Dr Jose Eleuterio Gonzalez

🇲🇽

Monterrey, Mexico

Eukarya Pharmasite

🇲🇽

Monterrey, Mexico

Arke Estudios Clinicos SA de CV

🇲🇽

Veracruz, Mexico

Universitair Medisch Centrum Groningen

🇳🇱

Groningen, Netherlands

Waikato Hospital

🇳🇿

Hamilton, New Zealand

Southern Philippines Medical Center -Davao-62091

🇵🇭

Davao City, Philippines

Center for Skin Research, Testing and Product Development

🇵🇭

Makati City, Philippines

Philippine General Hospital

🇵🇭

Manila, Philippines, Philippines

East Avenue Medical Center

🇵🇭

Quezon City, Philippines

Non-Public Health Care Facility LABDERM

🇵🇱

Ossy, Poland

NSZOZ Termedica Clinical Research Center

🇵🇱

Poznan, Poland

Frederic Chopin University Hospital No. 1 in Rzeszow

🇵🇱

Rzeszow, Poland

High-Med Specialist Clinic, Warsaw

🇵🇱

Warsaw, Poland

National Medical Institute MSWiA

🇵🇱

Warsaw, Poland

Provita Clinic

🇵🇱

Warsaw, Poland

Royalderm

🇵🇱

Warszawa, Poland

Centrum Zdrowia WroMedica

🇵🇱

Wroclaw, Poland

National University Hospital-Singapore-42005

🇸🇬

Singapore, Singapore

DOST sro - Sanatorium-Type Dermatovenereological Department

🇸🇰

Svidnik, Slovakia

FN Trnava

🇸🇰

Trnava, Slovakia

TASK Applied Science

🇿🇦

Cape Town, South Africa

Hospital Santa Creu i Sant Pau

🇪🇸

Barcelona, Spain

Hospital Universitario Reina Sofía-Córdoba-40500

🇪🇸

Córdoba, Spain

Hospital Universitario San Cecilio

🇪🇸

Granada, Spain

Hospital General de Granollers

🇪🇸

Granollers, Spain

Hospital General Universitario Gregorio Marañón

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Hospital de Manises

🇪🇸

Manises, Spain

Hospital Universitario de Salamanca

🇪🇸

Salamanca, Spain

Complexo Hospitalario Universitario De Santiago

🇪🇸

Santiago de Compostela, Spain

Hospital Miguel Servet

🇪🇸

Zaragoza, Spain

University Hospital Basel

🇨🇭

Basel, Switzerland

University Hospital Bern/Inselspital Bern

🇨🇭

Bern, Switzerland

Hôpitaux Universitaires Genève (HUG) Dermatologie et vénéréologie

🇨🇭

Geneve, Switzerland

Chang Gung Memorial Hospital(Linkou)

🇨🇳

TaoYuan, Taiwan

SBU Gulhane Training and Research Hospital

🇹🇷

Ankara, Turkey

Akdeniz University Medical Faculty

🇹🇷

Antalya, Turkey

Ondokuz Mayis Universitesi Tip Fakultesi

🇹🇷

Samsun, Turkey

Gloucestershire Royal Hospital

🇬🇧

Gloucester, United Kingdom

St George's Hospital-London-26733

🇬🇧

London, United Kingdom

HCMC Hospital of Dermato-Venereology-Ho Chi Minh-66092

🇻🇳

Ho Chi Minh, Vietnam

© Copyright 2025. All Rights Reserved by MedPath